Cannabis Science, Inc., (CBIS) a U.S. company specializing in the development of cannabinoid-based medicines, has entered into an expanded 5-year, $1.8 million Research Collaboration Agreement (RCA) with Dana Farber Cancer Institute, Inc., encompassing operating procedures and related communication activities. The work will be focused on essentially the same clinical targets with expanded work parameters based on current laboratory success.
Cannabis Science’s current laboratory research forms part of an aggressive drug development pipeline targeting critical ailments from laboratory research to scientific publication that Cannabis Science is developing with its research partners. This strongly demonstrates and effects the Company’s strong commitment to cutting-edge cannabinoid science in its pharmaceutical development programs. Cannabis Science has developed this pipeline to ensure that the Company’s research work reaches the scientific community and the patients in a timely fashion.
“Currently our funded research focuses on the clinical applications of cannabinoids in cancer treatment and pain management, but we will expand our portfolio in the following significant directions: (a) we will investigate the effectiveness of cannabinoid treatment in an increasing array of cancers, especially difficult to treat cancers and those with high fatality rates, (b) we will develop novel targeted delivery methods in the use of cannabinoids, and (c) we will, with advances in bioinformatics, computer science, and pharmacology, explore the mechanisms of action of cannabinoids in the management of disease,” stated Dr. Allen A. Herman, CBIS’ Chief Medical Officer (CMO).
The CBIS/Dana-Farber relationship will leverage the collective experience and expertise of both organizations to jointly develop cannabinoid-based medications and associated delivery technologies for the treatment of cancers, and potentially other indications. “I am extremely excited about our expanded agreement with Dana-Farber,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “We now have a more comprehensive framework in place with Dana-Farber that will enable us to focus on the science of cannabinoids. We believe we are uniquely positioned to help push forward the research and development of cannabinoid-based medicines and delivery systems to treat cancers, and potentially other ailments.”
CBIS entered into an initial research agreement with Dana-Farber in January 2017, and a second agreement in April 2017. As a result of this collaboration, CBIS and Dana-Farber have published initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the cancer research journal, Frontiers in Oncology. This publication titled, "Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids," addresses drug delivery, and highlights an innovative strategy to transport cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.
"This publication reflects our initial work and we are assiduously working on using our drug delivery system to examine the effect of cannabinoids with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the FDA. As we continue this research, we will expand our pharmaceutical development program from farm to bedside," concluded Dr. Herman.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report'sBest Hospitals for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women's Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique 50/50 balance between cancer research and care, and much of the Institute's work is dedicated to translating the results of its discovery into new treatments for patients in Boston, and around the world.
About the CBIS/Dana-Farber Relationship
· Cannabis Science, Inc. (CBIS) has a 5-year, $1.8 million Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc., which expands the scope and funding of an initial RCA between CBIS and Dana-Farber signed in January 2017. Leveraging the collective experience and expertise of both organizations, CBIS and Dana-Farber intend to jointly develop cannabinoid-based medications and associated delivery technologies for the treatment of cancers, and potentially other indications.
· The CBIS/Dana-Farber relationship will leverage the collective experience and expertise of both organizations to jointly develop cannabinoid-based medications and associated delivery technologies for the treatment of cancers, and potentially other indications.
· The CBIS/Dana-Farber Research Collaboration Agreement was formed to jointly develop cannabinoid- based medications targeting cancers and other critical ailments.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.